英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
percipi查看　percipi　在百度字典中的解释百度英翻中〔查看〕
percipi查看　percipi　在Google字典中的解释Google英翻中〔查看〕
percipi查看　percipi　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA Approves Cavhanza for PH-positive Chronic Myeloid Leukemia
    The FDA has approved Cavhanza (nilotinib), a new orally disintegrating tablet formulation for adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), according to an announcement from Cycle Pharmaceuticals
  • Now FDA approved: A new treatment option for Ph+ CML
    Indications CAVHANZA (nilotinib) is a kinase inhibitor indicated for the treatment of: Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) Adults with CP Ph+ CML or accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy
  • Cycle Pharmaceuticals | FDA approval of CAVHANZA
    CAVHANZA (nilotinib) is a kinase inhibitor indicated for the treatment of: Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
  • FDA Approves Cavhanza, an ODT Formulation of Nilotinib for . . .
    Cavhanza, a BCR-ABL tyrosine kinase inhibitor, is approved for the treatment of adults with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP
  • CAVHANZA™ (nilotinib) Orally Disintegrating Tablets: A New . . .
    This will be a first in the nilotinib market, addressing a known challenge in Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) treatment, where 25% of patients are co-prescribed PPIs or H₂RAs – medications that can compromise treatment efficacy 3 In clinical trials, CAVHANZA demonstrated no food effect and can be taken without regard to meals, reducing food-related
  • FDA Approves Oral Nilotinib Tablets for Ph+ CML
    The U S Food and Drug Administration (FDA) has approved Cavhanza, orally disintegrating nilotinib tablets, marking a significant shift in the management of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) Developed by Cycle Pharmaceuticals in collaboration with Flex Pharma, this new formulation of the second-generation tyrosine kinase inhibitor (TKI) addresses long
  • FDA Approves Nilotinib With No Mealtime Restrictions in Ph . . .
    The FDA granted approval to nilotinib (Danziten) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and adult patients with chronic phase (CP) and acute phase (AP) This indication is intended for patients who are resistant or intolerant to prior therapy that included imatinib (Gleevec) This marks the
  • CAVHANZA™ (nilotinib) Orally . . . - FinancialContent
    Indications CAVHANZA (nilotinib) is a kinase inhibitor indicated for the treatment of: Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) Adults with CP Ph+ CML or accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy Contraindications
  • redacted - accessdata. fda. gov
    The treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase The treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib
  • WebMD Drug Updates Approvals
    June 3, 2026 — The FDA has approved Cavhanza (nilotinib), a new orally disintegrating tablet, for adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)





中文字典-英文字典  2005-2009